{"title":"安罗替尼联合苯美司托巴特和化疗对ES-SCLC有效","authors":"Diana Romero","doi":"10.1038/s41571-024-00931-w","DOIUrl":null,"url":null,"abstract":"<p>Patients with extensive-stage small-cell lung cancer (ES-SCLC) usually receive platinum-based chemotherapy plus an immune-checkpoint inhibitor (ICI) as first-line therapy, although disease relapse is a concern. Now, data from the phase III ETER701 trial demonstrate that the combination of the anti-angiogenic agent anlotinib plus the anti-PD-L1 antibody benmelstobart and chemotherapy has promising efficacy in this setting.</p><p>Patients were randomly allocated to receive anlotinib plus benmelstobart and chemotherapy (triplet regimen; <i>n</i> = 246), anlotinib plus placebo and chemotherapy (doublet regimen; <i>n</i> = 245) or double placebo plus chemotherapy (the standard of care in China at the time of trial design) (<i>n</i> = 247). Progression-free survival (PFS) and overall survival (OS) were the co-primary end points.</p>","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":81.1000,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Anlotinib plus benmelstobart and chemotherapy are effective in ES-SCLC\",\"authors\":\"Diana Romero\",\"doi\":\"10.1038/s41571-024-00931-w\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Patients with extensive-stage small-cell lung cancer (ES-SCLC) usually receive platinum-based chemotherapy plus an immune-checkpoint inhibitor (ICI) as first-line therapy, although disease relapse is a concern. Now, data from the phase III ETER701 trial demonstrate that the combination of the anti-angiogenic agent anlotinib plus the anti-PD-L1 antibody benmelstobart and chemotherapy has promising efficacy in this setting.</p><p>Patients were randomly allocated to receive anlotinib plus benmelstobart and chemotherapy (triplet regimen; <i>n</i> = 246), anlotinib plus placebo and chemotherapy (doublet regimen; <i>n</i> = 245) or double placebo plus chemotherapy (the standard of care in China at the time of trial design) (<i>n</i> = 247). Progression-free survival (PFS) and overall survival (OS) were the co-primary end points.</p>\",\"PeriodicalId\":19079,\"journal\":{\"name\":\"Nature Reviews Clinical Oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":81.1000,\"publicationDate\":\"2024-07-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Reviews Clinical Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41571-024-00931-w\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41571-024-00931-w","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
Anlotinib plus benmelstobart and chemotherapy are effective in ES-SCLC
Patients with extensive-stage small-cell lung cancer (ES-SCLC) usually receive platinum-based chemotherapy plus an immune-checkpoint inhibitor (ICI) as first-line therapy, although disease relapse is a concern. Now, data from the phase III ETER701 trial demonstrate that the combination of the anti-angiogenic agent anlotinib plus the anti-PD-L1 antibody benmelstobart and chemotherapy has promising efficacy in this setting.
Patients were randomly allocated to receive anlotinib plus benmelstobart and chemotherapy (triplet regimen; n = 246), anlotinib plus placebo and chemotherapy (doublet regimen; n = 245) or double placebo plus chemotherapy (the standard of care in China at the time of trial design) (n = 247). Progression-free survival (PFS) and overall survival (OS) were the co-primary end points.
期刊介绍：
Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
